Ocular Therapeutix, Inc. (OCUL)
| Market Cap | 2.03B |
| Revenue (ttm) | 51.95M |
| Net Income (ttm) | -265.94M |
| Shares Out | 217.69M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,958,749 |
| Open | 9.59 |
| Previous Close | 9.52 |
| Day's Range | 9.21 - 9.75 |
| 52-Week Range | 6.23 - 16.44 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 23.56 (+152.79%) |
| Earnings Date | May 5, 2026 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ... [Read more]
Financial Performance
In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price target is $23.56, which is an increase of 152.79% from the latest price.
News
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Transcript: HCW @ Home
AXPAXLI's phase III SOL-1 trial met robust superiority and safety endpoints, supporting a single pivotal trial approval pathway for wet AMD. The drug's unique profile and commercial readiness position it for broad adoption and premium pricing, with ongoing trials and a strong IP portfolio supporting long-term growth.
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 Ocular's Investor Day will take place in New York City, with v...
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference
AXPAXLI's phase III SOL-1 trial demonstrated robust superiority over anti-VEGF, earning strong medical and strategic interest. Safety concerns about floaters were addressed with data, and regulatory confidence is high for FDA approval based on SOL-1 alone, with SOLAR expected to further support commercial adoption.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026
AXPAXLI achieved the first-ever phase III superiority result over anti-VEGF therapy in wet AMD, with robust disease control and a strong safety profile. Regulatory submission is underway, supported by a single pivotal trial and a solid financial position, with further updates expected as the SOLAR study progresses.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference
A first-ever superiority study in retina met its primary endpoint with robust data consistency and unprecedented disease control. The drug is expected to secure a unique superiority label, supporting premium pricing and broad coverage for diabetic retinal diseases, with a favorable safety profile and strong real-world potential.
Ocular Therapeutix Transcript: Study update
AXPAXLI demonstrated statistically significant superiority over aflibercept in maintaining vision and disease control for up to 12 months in wet AMD, with a favorable safety profile and no serious adverse events. Regulatory submission is planned based on SOL-1 alone, with broad clinical adoption anticipated.
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigatio...
Ocular Therapeutix Transcript: Study result
SOL-1 phase 3 results show AXPAXLI achieved statistical superiority over aflibercept in wet AMD, with 74.1% maintaining vision at week 36 and strong anatomic control. The drug was well-tolerated, with no serious safety concerns, and is positioned for rapid adoption and regulatory submission.
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial...
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSW...
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug
Ocular Therapeutix Inc. (NASDAQ: OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the trea...
Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference
Two phase III trials, SOL-1 and SOL-R, aim to secure a superiority label and address sustainability and long-term outcomes in retinal diseases. Strategic trial design, regulatory alignment, and a novel approach to diabetic retinopathy position the therapy for broad adoption and market impact.
Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025
Two pivotal phase III trials for a novel retinal therapy are progressing, with regulatory submission planned post-2027. The lead asset, AXPAXLI, targets wet AMD and diabetic retinopathy with a unique hydrogel platform and aims for broad market adoption.
Ocular Therapeutix Earnings Call Transcript: Q3 2025
Advanced pivotal trials for XPAXLY in Wet AMD and diabetic retinopathy, with SOLAR reaching full enrollment and strong execution in SOL1. Recent financing extends cash runway into 2028, supporting broad label pursuit and commercial readiness.
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potentia...
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix Transcript: Investor Day 2025
AXPAXLI is positioned to become the first retinal therapy with a superiority label, targeting both wet AMD and diabetic retinopathy with innovative, durable dosing and robust clinical trial designs. The company’s strategy leverages regulatory alignment, market expansion, and a novel clinical endpoint to drive rapid adoption and long-term value.
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experie...